Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2024-198763

Published: 2024

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Blood (2022) 140 (Supplement 1): 818–820.

https://doi.org/10.1182/blood-2022-162252

Published: 2022

Journal Articles

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Annamaria Brioli, MD, Kirsi Manz, Mathias Hänel, MD, Markus Pfirrmann, PhD, Andreas Christoph Schwarzer, MD, Marie von Lilienfeld-Toal, MD, Gabriele Prange-Krex, Christian Fabisch, PhD, Stefan Knop, Thomas Illmer, MD, Beate Krammer-Steiner, Andreas Hochhaus, MD, Lars-Olof Mügge, MD

Blood (2018) 132 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2018-99-115964

Published: 2018

Journal Articles

Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients

Annamaria Brioli, MD, vom Hofe Felix, Lars-Olof Mügge, MD, Sebastian Scholl, MD, Inken Hilgendorf, MD, Herbert G. Sayer, MD PhD, Olaposi Yomade, MD, Thomas Ernst, Andreas Hochhaus, MD, Marie von Lilienfeld-Toal, MD

Blood (2018) 132 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2018-99-112045

Published: 2018

Journal Articles

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Elena Zamagni, Giuseppe Bandini, Annalisa Pezzi, PhD, Paola Tacchetti, Ilaria Rizzello, Lucia Pantani, Mario Arpinati, MD PhD, Beatrice A Zannetti, MD, Serena Rocchi, Mariarosaria Sessa, Annamaria Brioli, Katia Mancuso, Carolina Terragna, PhD, Nicoletta Testoni, Francesca Bonifazi, Michele Cavo, MD

Blood (2015) 126 (23): 1968.

https://doi.org/10.1182/blood.V126.23.1968.1968

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

Journal Articles

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Charlotte Pawlyn, Lorenzo Melchor, Alex Murison, Christopher P. Wardell, Annamaria Brioli, Eileen M. Boyle, Martin F. Kaiser, Brian A. Walker, Dil B. Begum, Nasrin B. Dahir, Paula Proszek, Walter M. Gregory, Mark T. Drayson, Graham H. Jackson, Fiona M. Ross, Faith E. Davies, Gareth J. Morgan

Blood (2015) 125 (5): 831–840.

https://doi.org/10.1182/blood-2014-07-584268

Published: 2015

Includes: Supplemental data

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Marina Martello, PhD, Angela Flores Dico, Daniel Remondini, PhD, Giovanni Martinelli, MD, Enrica Borsi, PhD, Barbara Santacroce, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Anna Beatrice Zannetti, MD, Katia Mancuso, MD, Serena Rocchi, MD, Annalisa Pezzi, Statistician, Nicoletta Testoni, PhD, Giulia Marzocchi, PhD, Gaia Ameli, Michele Cavo, MD, Carolina Terragna, PhD

Blood (2014) 124 (21): 2054.

https://doi.org/10.1182/blood.V124.21.2054.2054

Published: 2014

Journal Articles

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

John Jones, MD, Charlotte Pawlyn, MBBChir, Annamaria Brioli, David A Cairns, PhD, Ana Quartillo, Rachel Sigsworth, Helen Howard, PhD, Corinne Collett, Jacqueline Ouzman, PhD, Walter Gregory, PhD, Nigel Russell, Graham H Jackson, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 4744.

https://doi.org/10.1182/blood.V124.21.4744.4744

Published: 2014

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Blood (2014) 124 (21): 3400.

https://doi.org/10.1182/blood.V124.21.3400.3400

Published: 2014

Journal Articles

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Gay, MD, Annalisa Pezzi, Statistician, Marilena Bellò, MD, Ilaria Rambaldi, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Valeria Magarotto, MD, Beatrice Anna Zannetti, MD, Massimo Menga, MD, Giulia Marzocchi, PhD, Carolina Terragna, PhD, Katia Mancuso, MD, Antonio Palumbo, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2014) 124 (21): 3371.

https://doi.org/10.1182/blood.V124.21.3371.3371

Published: 2014

Journal Articles

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Annamaria Brioli, Hannah Giles, Charlotte Pawlyn, John P. Campbell, Martin F. Kaiser, Lorenzo Melchor, Graham H. Jackson, Walter M. Gregory, Roger G. Owen, J. Anthony Child, Faith E. Davies, Michele Cavo, Mark T. Drayson, Gareth J. Morgan

Blood (2014) 123 (22): 3414–3419.

https://doi.org/10.1182/blood-2013-12-542662

Published: 2014

Journal Articles

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

Paola Tacchetti, MD, Serena Rocchi, MD, Annalisa Pezzi, Elena Zamagni, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Katia Mancuso, MD, Annamaria Brioli, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1859.

https://doi.org/10.1182/blood.V122.21.1859.1859

Published: 2013

Journal Articles

The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma

Eileen M Boyle, MD, Annamaria Brioli, MD, Xavier Leleu, MD, PhD, Gareth J Morgan, MD PhD, Charlotte Pawlyn, MD, Faith E Davies, MD, John P Campbell, PhD, Mark T Drayson, MD PhD

Blood (2013) 122 (21): 1895.

https://doi.org/10.1182/blood.V122.21.1895.1895

Published: 2013

Journal Articles

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Elena Zamagni, MD, Cristina Nanni, MD, Annalisa Pezzi, Statistics, Katia Mancuso, Paola Tacchetti, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Annamaria Brioli, MD, Serena Rocchi, MD, Giulia Marzocchi, PhD, Nicoletta Testoni, BS, Carolina Terragna, PhD, Giovanni Martinelli, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1936.

https://doi.org/10.1182/blood.V122.21.1936.1936

Published: 2013

Journal Articles

Seralite© Rapid Point-Of-Care Detection Of Free Light Chain Escape, Non-Secretory Relapse and Light Chain Only Relapse In Multiple Myeloma

John P Campbell, PhD, Ann E Stride, PhD, Annamaria Brioli, MD, Margaret Goodall, PhD, Gareth J Morgan, MD PhD, Mark T Drayson, MD PhD

Blood (2013) 122 (21): 3136.

https://doi.org/10.1182/blood.V122.21.3136.3136

Published: 2013

NARROW

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Seralite© Rapid Point-Of-Care Detection Of Free Light Chain Escape, Non-Secretory Relapse and Light Chain Only Relapse In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only